Abstract P1-23-02: Incidence, clinicopathological features and treatment patterns of male breast cancer (MBC) in a high-volume cancer center in the United Arab Emirates (UAE)
Authors: Al-Awadhi Aydah , Yousif Ali , Balalaa Nahed , Luiten Ernest , Jelovac Danijela 
Published: March 2022

Introduction:Breast cancer incidence in males is rare. MBC remains understudied and treatment recommendations are generally extrapolated from larger trials in women. Characteristics and incidence of the disease vary widely between countries. Tawam Hospital has been the first and the major provider of cancer care in The UAE for over four decades. The epidemiology and characteristics of MBC in The UAE is rather unknown to date. Objective:This study was conducted to investigate the incidence, clinical presentation, pathological characteristics, and treatment patterns of MBC at the major cancer center in the UAE, Tawam Hospital. This will provide a better insight in local features and enables comparison of The UAE data with other parts of the world. Method: We retrospectively analyzed data of MBC treated at The Tawam Hospital between 2000 and 2020. Information was obtained from The Tawam Hospital Cancer Registry and analyzed using excel software.Results:A total of 28 patients with MBC were identified. Male breast cancer consists of 0.75% (28 out of 3733 cases) of all breast cancer cases diagnosed between 2000 - 2020 at the Tawam Hospital. The clinical and the pathological characteristics of these patients are provided in table 1. Only 10 (35%) patients had germline genetics testing and 2 had pathogenic mutation in BRCA1/2 genes. All of the patients presented with palpable mass. Majority of the patients had Grade 2 (57%) or Grade 3 (29%) disease and 15 (54%) had positive lymph nodes at the time of diagnosis. Of the 28 patients, 2 presented with de novo metastatic disease and 26 presented with localized disease. Out of these 26 patients, 22(85%) underwent modified radical mastectomy, 4(15%) had lumpectomy , 17(65%) had axillary lymph node dissection, 9(35%) had sentinel lymph node biopsy, 16(61.5%) had adjuvant radiation therapy, 16(61.5%) had adjuvant chemotherapy and hormonal therapy, 7(27%) had adjuvant hormonal therapy only and 3(11.5%) did not receive adjuvant systemic therapy (2 refused and 1 with hormonal receptor negative DCIS). All of the patients who received hormonal therapy had tamoxifen. about 60% of the patients with localized disease received multimodality treatment including all surgery, radiation therapy and systemic therapy.Recurrent metastatic disease developed in 19% (5 out 26) of the patients. Out of 7 MBC with de novo and recurrent metastatic disease, 3 had bone metastases only, 3 had bone and visceral metastases and 1 was with locoregional recurrence.Conclusion:Our cohort indicates that the majority of the patients with MBC presented with higher grade, cT2 and above and node positive disease indicating the need for better awareness for early detection. Majority of the patients with localized disease received multimodality treatments. Patient outcome of this cohort will be presented at the meeting.

Table 1.Clinical and Pathological Characteristics of Male with Breast cancer (N=28)N(%)N(%)Median age51 (33 - 65)–Hormonal receptor/HER-2 status+/+5 (18)Clinical stage04 (14)+/-21 (75)I2 (7)-/+1 (3.5)II12 (43)-/-1 (3.5)III8 (29)GradeI4 (14)IV2 (7)II16 (57)Clinical node statusN013 (46.2)III8 (29)N17 (26)HistologyDCIS24 (86)N24 (14)IDC4 (14)N34 (14)Clinical T statusT0/is4 (14)T13 (11)T215 (54)T32 (7)T44 (14)

Citation Format: Aydah Al-Awadhi, Ali Yousif, Nahed Balalaa, Ernest Luiten, Danijela Jelovac. Incidence, clinicopathological features and treatment patterns of male breast cancer (MBC) in a high-volume cancer center in the United Arab Emirates (UAE) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-23-02.